RxDoctor Payments Data

Rashad Belin, MD

Interventional Cardiology · Olympia Fields, ILNPI 1508150418

Payments from drug & device makers

$4,194in general payments, 2019–2025

Across 98 payments — averaging $42.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Cardiovascular Systems Inc.$589
  • Johnson & Johnson$380
  • Novartis$209
  • Philips North America LLC$179
  • E.r. Squibb & Sons, L.L.C.$167
  • plus $790 from 14 others

What the payments were for

  • Grants$1554%
  • Travel & lodging$1,52636%
  • Food & beverage$2,45659%
  • Education$561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,194 in reported general payments places this provider in the 30th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$114,695
Medicare patients
706
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$138,202
EntrestoSacubitril/Valsartan115$105,431
JardianceEmpagliflozin72$83,431
Repatha SureclickEvolocumab43$42,080
XareltoRivaroxaban49$39,338
FarxigaDapagliflozin Propanediol22$19,547
Praluent PenAlirocumab17$12,510
BrilintaTicagrelor15$10,010
Atorvastatin Calcium411$3,428
Metoprolol Succinate297$3,223
Rosuvastatin Calcium269$2,223
FenofibrateFenofibrate Nanocrystallized101$2,058
Ezetimibe143$1,919
Spironolactone269$1,516
Amlodipine Besylate183$1,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$138,202171 claims
NovartisEntresto$209$105,431115 claims
Johnson & JohnsonXarelto$380$39,33849 claims
AstraZenecaFarxiga, Brilinta$40$29,55737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Olympia Fields

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →